Acadian Asset Management LLC Adaptimmune Therapeutics PLC Transaction History

Acadian Asset Management LLC

$48.4 Billion
Q2 2025

A detailed history of Acadian Asset Management LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Acadian Asset Management LLC holds 1,964,141 shares of ADAP stock, worth $510,676. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,964,141

Previous 2,218,215 11.45%

Holding current value

$510,676

Previous $424,000 8.25%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$0.22 - $0.32 $55,896 - $81,303	-254,074 Reduced 11.45%	1,964,141 $459,000
Q1 2025 May 21, 2025	BUY	$0.2 - $0.65 $341,599 - $1.11 Million	1,707,999 Added 334.76%	2,218,215 $424,000
Q4 2024 Feb 11, 2025	BUY	$0.54 - $0.95 $275,516 - $484,705	510,216 New	510,216 $269,000
Q2 2023 Aug 07, 2023	BUY	$0.9 - $1.51 $42,376 - $71,098	47,085 Added 15.14%	358,010 $329,000
Q1 2023 May 11, 2023	SELL	$1.06 - $2.16 $227,443 - $463,469	-214,569 Reduced 40.83%	310,925 $332,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $434,622 - $1.05 Million	413,926 Added 371.01%	525,494 $760,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $103,858 - $236,131	97,980 Added 721.08%	111,568 $116,000
Q2 2022 Aug 09, 2022	SELL	$1.33 - $2.28 $40,724 - $69,813	-30,620 Reduced 69.26%	13,588 $23,000
Q1 2022 May 12, 2022	BUY	$1.73 - $4.06 $76,479 - $179,484	44,208 New	44,208 $91,000
Q1 2021 May 11, 2021	SELL	$4.9 - $6.83 $1.48 Million - $2.06 Million	-301,408 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$4.0 - $9.2 $1.21 Million - $2.77 Million	301,408 New	301,408 $1.63 Million
Q3 2019 Nov 07, 2019	SELL	$1.43 - $3.81 $60,799 - $161,989	-42,517 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$3.23 - $5.41 $74,751 - $125,203	23,143 Added 119.45%	42,517 $170,000
Q1 2019 May 09, 2019	SELL	$3.63 - $6.06 $67,895 - $113,346	-18,704 Reduced 49.12%	19,374 $83,000
Q4 2018 Feb 07, 2019	BUY	$3.76 - $14.16 $143,173 - $539,184	38,078 New	38,078 $219,000
Q2 2018 Jul 24, 2018	SELL	$10.42 - $13.74 $286,633 - $377,959	-27,508 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$7.1 - $11.56 $80,918 - $131,749	11,397 Added 70.74%	27,508 $309,000
Q4 2017 Jan 18, 2018	SELL	$6.68 - $8.74 $60,193 - $78,756	-9,011 Reduced 35.87%	16,111 $108,000
Q3 2017 Oct 13, 2017	BUY	$4.93 - $8.93 $123,851 - $224,339	25,122	25,122 $206,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

116M

Call Options Held

10.3K

Put Options Held

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $42.5M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Adaptimmune Therapeutics PLC Transaction History